Finnish pharmaceutical company Orion Corporation (HEL:ORNBV) and biopharmaceutical company Glykos Finland Oy announced on Tuesday that they have extended their research and licensing agreement focused on the development of next-generation antibody-drug conjugates (ADCs).

The extended deal grants Orion access to Glykos' proprietary ADC technologies for up to three additional programmes, building on the original agreement that covered three ADC programmes. Orion will lead target selection, research, development and commercialisation of the new ADC candidates, with an emphasis on solid tumour therapies.

Financial terms for the additional programmes remain consistent with the original agreement. Glykos will receive milestone payments tied to development progress and product sales, as well as royalties from commercial sales.

The partnership aims to advance Orion's pipeline in oncology while leveraging Glykos' technology platform for innovative cancer treatments.